Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease
出版年份 2022 全文链接
标题
Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease
作者
关键词
-
出版物
Current Atherosclerosis Reports
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-05-04
DOI
10.1007/s11883-022-01027-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effect of Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
- (2021) Pichamol Jirapinyo et al. Clinical Gastroenterology and Hepatology
- The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis
- (2021) Manal F. Abdelmalek et al. Contemporary Clinical Trials
- Therapeutic pipeline in nonalcoholic steatohepatitis
- (2021) Raj Vuppalanchi et al. Nature Reviews Gastroenterology & Hepatology
- Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis
- (2021) Chloe Wong et al. Frontiers in Endocrinology
- Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double‐Blind Phase 2 Trial
- (2021) Samer Gawrieh et al. HEPATOLOGY
- Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis
- (2021) Federico Salomone et al. LIVER INTERNATIONAL
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis
- (2021) Chloe Wong et al. Frontiers in Endocrinology
- A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Non-alcoholic Fatty Liver Disease
- (2021) Jonathan Zhi Kai Toh et al. Clinical Gastroenterology and Hepatology
- A clinical overview of non‐alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non‐specialist needs to know
- (2021) Mark D. Muthiah et al. DIABETES OBESITY & METABOLISM
- TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
- (2021) Rohit Loomba et al. GASTROENTEROLOGY
- Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
- (2021) Alessandro Mantovani et al. Lancet Gastroenterology & Hepatology
- Is Fatty Liver Associated With Depression? A Meta-Analysis and Systematic Review on the Prevalence, Risk Factors, and Outcomes of Depression and Non-alcoholic Fatty Liver Disease
- (2021) Jieling Xiao et al. Frontiers in Medicine
- Trends in statin utilisation in US adults with non‐alcoholic fatty liver disease
- (2021) Jacqueline B. Henson et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials
- (2021) Cheng Han Ng et al. Endocrine Practice
- Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis
- (2021) Ali Aminian et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
- (2021) Sven M. Francque et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results
- (2020) K.J. Lucas et al. DIGESTIVE AND LIVER DISEASE
- Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis
- (2020) Cristy R.C. Verzijl et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Burden of Disease due to Nonalcoholic Fatty Liver Disease
- (2020) Mark D. Muthiah et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials
- (2020) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Current management of non‐alcoholic steatohepatitis
- (2020) Mark D. Muthiah et al. LIVER INTERNATIONAL
- Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
- (2020) Jean-François Dufour et al. GUT
- Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
- (2020) Stephen A. Harrison et al. GASTROENTEROLOGY
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
- (2020) Rohit Loomba et al. HEPATOLOGY
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- (2019) Scott M. Grundy et al. CIRCULATION
- Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis
- (2019) Alessandro Mantovani et al. LIVER INTERNATIONAL
- Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events
- (2019) Sean L. Zheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis
- (2019) Stephen A. Harrison et al. HEPATOLOGY
- Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
- (2019) Maria J. Pereira et al. DRUGS
- Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease
- (2019) Tracey G. Simon et al. Clinical Gastroenterology and Hepatology
- Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes
- (2019) Kenneth Cusi HEPATOLOGY
- Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
- (2019) Philip Newsome et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
- (2019) Fernando Bril et al. DIABETES CARE
- Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease
- (2019) Dimitrios A. Koutoukidis et al. JAMA Internal Medicine
- Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know?
- (2019) Stefania Kiapidou et al. Annals of Hepatology
- Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
- (2019) M.S. Capehorn et al. DIABETES & METABOLISM
- CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
- (2019) Paul J. Pockros et al. LIVER INTERNATIONAL
- Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
- (2019) Rohit A. Sinha et al. THYROID
- Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
- (2019) Marcos Pedrosa et al. Contemporary Clinical Trials
- MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
- (2019) Michael A Nauck et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy
- (2019) Xinyang Yu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
- (2019) Naga Chalasani et al. GASTROENTEROLOGY
- A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Significant improvement in cardiometabolic health in healthy nonobese individuals during caloric restriction-induced weight loss and weight loss maintenance
- (2018) Jasper Most et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes
- (2018) Fernando Bril et al. Clinical Gastroenterology and Hepatology
- Treatment of Dyslipidemia in Common Liver Diseases
- (2018) Elizabeth K. Speliotes et al. Clinical Gastroenterology and Hepatology
- The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
- (2018) Merlin C. Thomas et al. DIABETOLOGIA
- Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
- (2018) Stephen A. Harrison et al. GASTROENTEROLOGY
- Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
- (2018) Mohammad Shadab Siddiqui et al. HEPATOLOGY
- Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure
- (2018) Filippo Valbusa et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Mechanisms of NAFLD development and therapeutic strategies
- (2018) Scott L. Friedman et al. NATURE MEDICINE
- Direct effects of thyroid hormones on hepatic lipid metabolism
- (2018) Rohit A. Sinha et al. Nature Reviews Endocrinology
- Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts
- (2018) Ramón Estruch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition
- (2018) Debapriya Basu et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-Analysis
- (2018) Yung Lee et al. Clinical Gastroenterology and Hepatology
- Prevalence and Severity of Nonalcoholic Fatty Liver Disease (NAFLD) Among Caregivers of Patients with NAFLD Cirrhosis
- (2018) Mohammad Shadab Siddiqui et al. Clinical Gastroenterology and Hepatology
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
- (2018) Rohit Loomba et al. GASTROENTEROLOGY
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss
- (2018) Frank L. Greenway et al. Obesity
- Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
- (2018) Edgar D. Charles et al. Obesity
- Long-Term Outcomes After Bariatric Surgery: a Systematic Review and Meta-analysis of Weight Loss at 10 or More Years for All Bariatric Procedures and a Single-Centre Review of 20-Year Outcomes After Adjustable Gastric Banding
- (2018) Paul E. O’Brien et al. OBESITY SURGERY
- Risk of Suicide and Self-harm Is Increased After Bariatric Surgery—a Systematic Review and Meta-analysis
- (2018) Daniel Castaneda et al. OBESITY SURGERY
- Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases
- (2017) Leon A Adams et al. GUT
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review
- (2017) Ryuki Hashida et al. JOURNAL OF HEPATOLOGY
- Treatment of NAFLD with diet, physical activity and exercise
- (2017) Manuel Romero-Gómez et al. JOURNAL OF HEPATOLOGY
- Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
- (2017) Zobair Younossi et al. Nature Reviews Gastroenterology & Hepatology
- Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease
- (2017) Giovanni Targher et al. Nature Reviews Nephrology
- Improvement of impaired diastolic left ventricular function after diet-induced weight reduction in severe obesity
- (2017) Sevda Karimian et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure
- (2017) Filippo Valbusa et al. PLoS One
- Liver Fat, Hepatic Enzymes, Alkaline Phosphatase and the Risk of Incident Type 2 Diabetes: A Prospective Study of 132,377 Adults
- (2017) Sean Chun-Chang Chen et al. Scientific Reports
- Aspirin use is associated with lower indices of liver fibrosis among adults in the United States
- (2016) Z. Gordon Jiang et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population
- (2016) Marcello Ricardo Paulista Markus et al. ATHEROSCLEROSIS
- Nonalcoholic Fatty Liver Disease Is Associated With Ventricular Arrhythmias in Patients With Type 2 Diabetes Referred for Clinically Indicated 24-Hour Holter Monitoring
- (2016) Alessandro Mantovani et al. DIABETES CARE
- A “systems medicine” approach to the study of non-alcoholic fatty liver disease
- (2016) Salvatore Petta et al. DIGESTIVE AND LIVER DISEASE
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
- (2016) Giovanni Targher et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Management of obesity
- (2016) George A Bray et al. LANCET
- Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure
- (2016) Filippo Valbusa et al. MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nonalcoholic fatty liver disease - A multisystem disease?
- (2016) Ivana Mikolasevic et al. WORLD JOURNAL OF GASTROENTEROLOGY
- FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease
- (2015) Rotonya M. Carr et al. Current Atherosclerosis Reports
- Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia
- (2015) Pierre Blais et al. DIGESTIVE DISEASES AND SCIENCES
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
- (2015) Eduardo Vilar-Gomez et al. GASTROENTEROLOGY
- NAFLD: A multisystem disease
- (2015) Christopher D. Byrne et al. JOURNAL OF HEPATOLOGY
- Effect of aerobic exercise training dose on liver fat and visceral adiposity
- (2015) Shelley E. Keating et al. JOURNAL OF HEPATOLOGY
- Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial
- (2015) Curtis K. Argo et al. JOURNAL OF HEPATOLOGY
- Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk
- (2015) Ehimen C. Aneni et al. JOURNAL OF HYPERTENSION
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Effect of Weight Loss Induced by Intragastric Balloon Therapy on Cardiac Function in Morbidly Obese Individuals: A Pilot Study
- (2015) Fatih Koc et al. MEDICAL PRINCIPLES AND PRACTICE
- Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease
- (2015) Alessandro Mantovani et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Republished: Non-alcoholic fatty liver disease: a practical approach to treatment
- (2015) J K Dyson et al. POSTGRADUATE MEDICAL JOURNAL
- Impact of obesity on cardiac metabolism, fibrosis, and function
- (2015) Rajiv Mahajan et al. TRENDS IN CARDIOVASCULAR MEDICINE
- Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome
- (2015) Konstantinos Kargiotis WORLD JOURNAL OF GASTROENTEROLOGY
- Practice patterns in NAFLD and NASH: real life differs from published guidelines
- (2015) Mary E. Rinella et al. Therapeutic Advances in Gastroenterology
- Total Body Weight Loss of ≥10 % Is Associated with Improved Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis
- (2014) Lisa M. Glass et al. DIGESTIVE DISEASES AND SCIENCES
- Clinical association between non-alcoholic fatty liver disease and the development of hypertension
- (2014) Jae-Hong Ryoo et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Lifestyle-Induced Decrease in Fat Mass Improves Adiponectin Secretion in Obese Adults
- (2014) KAREN R. KELLY et al. MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
- Enhancing the role of nutrition professionals in weight management: A cross-sectional survey
- (2014) Sara N. Bleich et al. Obesity
- Nonalcoholic Fatty Liver Disease Is Associated with Aortic Valve Sclerosis in Patients with Type 2 Diabetes Mellitus
- (2014) Stefano Bonapace et al. PLoS One
- Ventricular remodelling post-bariatric surgery: is the type of surgery relevant? A prospective study with 3D speckle tracking
- (2014) T. E. Kaier et al. European Heart Journal-Cardiovascular Imaging
- Liver steatosis (LS) evaluated through chemical-shift magnetic resonance imaging liver enzymes in morbid obesity; effect of weight loss obtained with intragastric balloon gastric banding
- (2013) Laura Folini et al. ACTA DIABETOLOGICA
- Hepatic Steatosis Is Associated With Aortic Valve Sclerosis in the General Population
- (2013) Marcello Ricardo Paulista Markus et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; Should we care?
- (2013) Ebenezer T. Oni et al. ATHEROSCLEROSIS
- The Addictive Dimensionality of Obesity
- (2013) Nora D. Volkow et al. BIOLOGICAL PSYCHIATRY
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
- (2013) Michael D. Jensen et al. CIRCULATION
- Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
- (2013) Maria Stepanova et al. DIGESTIVE DISEASES AND SCIENCES
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Extrahepatic complications of nonalcoholic fatty liver disease
- (2013) Matthew J. Armstrong et al. HEPATOLOGY
- Effects of Habitual Coffee Consumption on Cardiometabolic Disease, Cardiovascular Health, and All-Cause Mortality
- (2013) James H. O'Keefe et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
- (2013) Quentin M. Anstee et al. Nature Reviews Gastroenterology & Hepatology
- Blood alcohol concentrations rise rapidly and dramatically after Roux-en-Y gastric bypass
- (2013) Kristine J. Steffen et al. Surgery for Obesity and Related Diseases
- Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
- (2012) G. Musso et al. DIABETOLOGIA
- Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study
- (2012) Yin-Mei Lee et al. GASTROINTESTINAL ENDOSCOPY
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
- (2012) Naga Chalasani et al. HEPATOLOGY
- Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
- (2012) Katherine M. Flegal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy
- (2012) Rohit Anthony Sinha et al. JOURNAL OF CLINICAL INVESTIGATION
- Psychological dimensions after laparoscopic sleeve gastrectomy: reduced mental burden, improved eating behavior, and ongoing need for cognitive eating control
- (2012) Nicole Rieber et al. Surgery for Obesity and Related Diseases
- Effect of Bariatric Surgery on Cardiovascular Risk Profile†Drs. Heneghan and Meron-Eldar contributed equally to this article.
- (2011) Helen M. Heneghan et al. AMERICAN JOURNAL OF CARDIOLOGY
- Mechanisms Linking Nonalcoholic Fatty Liver Disease with Coronary Artery Disease
- (2011) W. Nseir et al. DIGESTIVE DISEASES AND SCIENCES
- Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort
- (2011) Matthew J. Armstrong et al. JOURNAL OF HEPATOLOGY
- Favorable Changes in Cardiac Geometry and Function Following Gastric Bypass Surgery
- (2011) Theophilus Owan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Diet and Exercise, Alone or Combined, on Weight and Body Composition in Overweight-to-Obese Postmenopausal Women
- (2011) Karen E. Foster-Schubert et al. Obesity
- Molecular mechanisms involved in hepatic steatosis and insulin resistance
- (2011) Takashi Matsuzaka et al. Journal of Diabetes Investigation
- A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease
- (2010) Giovanni Musso et al. HEPATOLOGY
- Acute stress reaction and completed suicide
- (2010) J. L. Gradus et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
- (2010) Giovanni Targher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
- (2010) W. Philip T. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype
- (2010) Shany Blum et al. PHARMACOGENOMICS
- Decreased survival of subjects with elevated liver function tests during a 28-year follow-up
- (2009) Cecilia Söderberg et al. HEPATOLOGY
- A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis
- (2009) Austin Nelson et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Health Outcomes of Gastric Bypass Patients Compared to Nonsurgical, Nonintervened Severely Obese
- (2009) Ted D. Adams et al. Obesity
- Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis
- (2009) Eugen Florin Georgescu et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver
- (2008) Nila Rafiq et al. Clinical Gastroenterology and Hepatology
- High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease
- (2008) K Kantartzis et al. GUT
- Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
- (2008) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Bariatric Surgery: Risks and Rewards
- (2008) Walter J. Pories JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline
- (2008) James L. Rosenzweig et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Vitamin E Supplementation Reduces Cardiovascular Events in a Subgroup of Middle-Aged Individuals With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 Genotype
- (2007) Uzi Milman et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease
- (2007) L. Spadaro et al. DIGESTIVE AND LIVER DISEASE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now